The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReabold Resources Regulatory News (RBD)

Share Price Information for Reabold Resources (RBD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.07
Bid: 0.065
Ask: 0.075
Change: 0.00 (0.00%)
Spread: 0.01 (15.385%)
Open: 0.07
High: 0.07
Low: 0.07
Prev. Close: 0.07
RBD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Formation of new division

5 Dec 2007 07:01

Adventis Group PLC05 December 2007 For release 7.00am 5th December 2007 Adventis Group plc (ATG/L) "Formation of New Market-Leading Healthcare Services Provider - Adventis Health Limited" Adventis Group plc ("Adventis" or the "Company"), the AIM-quoted full servicemultimedia marketing and advertising agency, announces that it has recentlyconsolidated its three healthcare creative and medical education agencies, whichformed the Adventis Healthcare services division, namely Affiniti Advertising,Roundhouse HealthAd and LeapFrog, into a new trading entity which will bebranded Adventis Health Limited ("Adventis Health"). Adventis Health will be run by three directors, namely Stuart Tennant, TimSchofield and Kevin McGetrick. All three have extensive healthcare andmanagement experience. This consolidation of Adventis Group's strength in the healthcare sector followson from the former division's earlier move into centralised premises inBeaconsfield, near to the M25 and M40, in August 2007 in addition to theCompany's existing offices in Hertford and Central London. Adventis Health, whose clients include, GSK, Pfizer, MSD, Roche, Novartis,Boehringer Ingelheim, Allergan, Baxter and Merck Serono, provides a range ofhighly skilled advertising and marketing services as well as medical education &PR programmes to the healthcare industry, targeted at both healthcareprofessionals and patients, in order to improve clients' sales and brandawareness. The Company anticipates that the formation of Adventis Health will create one ofthe industry's top five pharmaceutical industry service providers with aformidable, award-winning team of over 60 employees. The enlarged Healthcareservices operations will have the capability to provide a complete range ofintegrated marketing services, from medical education, to advertising, to newmedia. It will also provide the opportunity for an increased level ofcross-selling and the ability to provide multinational clients with a greaterlocal understanding of target markets. Charles Phillpot, Chief Executive of Adventis Group plc, commented: "The creation of this new platform servicing the healthcare sector is afantastic opportunity to leverage to the full our expertise in this arena. Wewill now be one of the few companies in the industry to offer a full servicemarketing capability and the ability to handle larger and more complex campaignsfor clients." -ENDS- Enquiries: Adventis Group PlcCharles Phillpot, CEO Tel: 020 7034 4750Peter Linnell, Finance Director Tel: 020 7034 4795 Adventis Financial PRChris Steele Tel: 020 7034 4759Tarquin Edwards Tel: 020 7034 4758 Editor's Note: Adventis Group plc provides a complete range of communications services,including corporate identity programmes, advertising campaigns, media andplanning and buying, literature, public relations, packaging, exhibitions,research and planning, interiors signage and digital media. The group employsc.150 staff in London and the southeast. Adventis has three divisions focusing on providing a range of services to theproperty, healthcare and financial sectors. Adventis Group was admitted to AIMin 2004. www.adventis.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Nov 20221:15 pmRNSCompletion of the Sale of Corallian to Shell
31st Oct 20229:08 amRNSPosting of Circular and Notice of Requisitioned GM
31st Oct 20227:00 amRNSPosting of Circular and Notice of Requisitioned GM
20th Oct 20227:00 amRNSRequisition of General Meeting
17th Oct 20221:00 pmRNSPurported Requisition of General Meeting
5th Oct 20223:30 pmRNSSPA for Sale of Corallian to Shell for £32 million
30th Sep 20227:00 amRNSUnaudited HY Results for 6 months ended 30/06/22
29th Sep 20227:02 amRNSPublication of PEDL183 CPR by RPS Energy
28th Sep 20227:00 amRNSConditional Acquisition of Simwell Resources
23rd Sep 20227:00 amRNSWest Newton Community Update on Planned Activity
23rd Sep 20227:00 amRNSWest Newton Community Update on Planned Activity
15th Sep 20227:00 amRNSAcquisition of North Sea Assets from Corallian
14th Sep 20227:00 amRNSAgreed Terms of Conditional Sale of Corallian
9th Sep 20224:40 pmRNSSecond Price Monitoring Extn
9th Sep 20224:35 pmRNSPrice Monitoring Extension
9th Sep 20227:00 amRNSResponse to Governmental Energy Plan
1st Sep 20227:00 amRNSUpdate on Corallian and acquisition of licences
14th Jul 20221:56 pmRNSHolding(s) in Company
1st Jul 20227:00 amRNSBoard Change
29th Jun 20224:31 pmRNSResults of Annual General Meeting
23rd Jun 20227:00 amRNSInvestor Presentation
21st Jun 20227:00 amRNSWest Newton Conceptual Development Plan
7th Jun 202211:53 amRNSNotice of AGM – correction of typographical error
1st Jun 202210:06 amRNSNotice of Annual General Meeting
27th May 20227:00 amRNSFull Year Results for the year ended 31 Dec 2021
26th May 20227:00 amRNSCompletion of Equity Exchange Agreement
24th May 20227:00 amRNSReabold North Sea – Presentation on New Licences
23rd May 20227:00 amRNSShareholder Approval Received for Equity Exchange
13th May 20227:00 amRNSAppointment of Chief Financial Officer
4th May 20227:00 amRNSOffer for Corallian and acquisition of licences
3rd May 20227:00 amRNSUpdate on Equity Exchange with Daybreak Oil & Gas
17th Mar 202212:21 pmRNSPlanning Application Approval for Next Phase
25th Feb 20227:00 amRNSInvestor Presentation
25th Feb 20227:00 amRNSUpdate on Equity Exchange with Daybreak Oil & Gas
24th Feb 20224:42 pmRNSSecond Price Monitoring Extn
24th Feb 20224:37 pmRNSPrice Monitoring Extension
17th Feb 202212:38 pmRNSAmendment of Existing Option Terms
25th Jan 20229:05 amRNSSecond Price Monitoring Extn
25th Jan 20229:00 amRNSPrice Monitoring Extension
17th Jan 20224:41 pmRNSSecond Price Monitoring Extn
17th Jan 20224:35 pmRNSPrice Monitoring Extension
17th Jan 20227:00 amRNSWest Newton Flow Rate Update
23rd Dec 20217:00 amRNSVictory – Submission of Draft FDP
2nd Dec 20212:00 pmRNSPrice Monitoring Extension
26th Nov 20217:00 amRNSWest Newton – Rathlin’s Update to Residents
22nd Oct 20217:00 amRNSDirectors’ Dealings
21st Oct 20217:00 amRNSCreation of Enhanced California E&P Company
20th Oct 202111:05 amRNSSecond Price Monitoring Extn
20th Oct 202111:00 amRNSPrice Monitoring Extension
20th Oct 20217:00 amRNSVictory CPR and Corallian Strategic Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.